Drugs / COVID-19 Convalscent Plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04474340 | May → Sep 2020 | viral pneumonia | Ministry of Health, Kuwait | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-19 Convalscent Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04474340 ↗ |
| Known as | convalescent plasma | “In the absence of licensed antiviral for COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered especially against RNA viruses .” NCT04474340 ↗ |
| Modality | Protein / enzyme biologic | “The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2” NCT04474340 ↗ |
| Route | Other | “How to transfuse CCP:” NCT04474340 ↗ |